Compare Twist Bioscience Corp (TWST) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Sprott Uranium Miners ETF — how do they compare? Twist Bioscience Corp trades at $158.89 (market cap $10.08B), while Sprott Uranium Miners ETF trades at $45.86 (market cap $1.87B). The key difference: Twist Bioscience Corp is far larger — about 5.4× Sprott Uranium Miners ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Sprott Uranium Miners ETF for 60 Days on average.
| TWST | URNM | |
|---|---|---|
Market Cap | $10.08B | $1.87B |
Volume | 4,229,037 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $205.00 | $83.99 |
52-Week Low | $25.45 | $46.09 |
Typical Hold Time | 27 Days | 60 Days |
Enterprise Value | $10.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
URNM (Sprott Uranium Miners ETF) trades at $47.87, down 4.83% today amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average indicators, though oscillators remain neutral. Recent news highlights uranium's long-term growth potential driven by AI energy demand and government nuclear investments, with spot uranium prices rising 21.25% over the past year according to Sprott Asset Management (September 2026).
The uranium sector shows strong fundamental tailwinds from nuclear energy expansion and AI power needs, but URNM's technical weakness suggests near-term volatility. Investment opportunity exists in uranium supply deficits and contracting growth, while risks include ETF concentration and commodity price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
